본문 바로가기
KERD
논문KCI 등재

순수 알츠하이머병 치매 환자군과 혼합성 치매 환자군에서 12개월간의 도네페질(Donepezil) 투여에 따른 치료 성적의 비교 평가

Comparative Assessment of Clinical Efficacy after 12-Month Clinical Trial of Donepezil between the Patients with Pure Alzheimer’s Disease and Mixed Dementia

김도관|이영민|정재원|김혜란|윤지혜|문유진|안인숙|황태영|강효신
대한노인정신의학회 (Korean Association For Geriatric Psychiatry)|2010.06|노인정신의학 (Journal of Korean Geriatric Psychiatry)|제14권 제1호|pp. 58-64

2

조회

0

다운로드

0

인용

0

참고문헌

초록

Objectives：The purpose of this study was to compare the efficacy of donepezil treatment between patients with pure Alzheimer’s disease (AD) and Mixed dementia (MD) during a 12-month trial. Methods：A total of 139 patients were recruited for this 52-week study. The effect of donepezil on cognitive function was measured using Alzheimer’s Disease Assessment Scale-cognitive subscale-preliminary Korean version (ADAS-cog-K). Patients’ activities of daily living using the Seoul-Instrumental Activities of Daily Living (S-IADL) and Seoul-Activities of Daily Living (S-ADL)；behavioral symptoms using the Korean version Neuropsychiatric Inventory (K-NPI) were measured at baseline, 13-weeks, 26-weeks, 39-weeks and 52-weeks. We defined the responsive patients to donepezil at those who showed a cognitive improvement or no change during the first six-month clinical trial. Results：84 pure AD patients and 34 MD patients were available for intent-to-treat (ITT) last observation carried forward (LOCF) analysis. There was no significant difference between two groups in mean change from baseline in the total ADAS-cog-k, S-ADL, SIADL and K-NPI scores at 52-week. Based on the operational criteria, 60.7% of pure AD patients and 58.8% of MD patients were responders to donepezil. Conclusion：MD patients had similar levels of efficacy with pure AD patients and donepezil was well tolerated in both groups. These results suggest that donepezil is an effective and well-tolerated treatment for MD patients as well as for pure AD patients.

Abstract

Objectives：The purpose of this study was to compare the efficacy of donepezil treatment between patients with pure Alzheimer’s disease (AD) and Mixed dementia (MD) during a 12-month trial. Methods：A total of 139 patients were recruited for this 52-week study. The effect of donepezil on cognitive function was measured using Alzheimer’s Disease Assessment Scale-cognitive subscale-preliminary Korean version (ADAS-cog-K). Patients’ activities of daily living using the Seoul-Instrumental Activities of Daily Living (S-IADL) and Seoul-Activities of Daily Living (S-ADL)；behavioral symptoms using the Korean version Neuropsychiatric Inventory (K-NPI) were measured at baseline, 13-weeks, 26-weeks, 39-weeks and 52-weeks. We defined the responsive patients to donepezil at those who showed a cognitive improvement or no change during the first six-month clinical trial. Results：84 pure AD patients and 34 MD patients were available for intent-to-treat (ITT) last observation carried forward (LOCF) analysis. There was no significant difference between two groups in mean change from baseline in the total ADAS-cog-k, S-ADL, SIADL and K-NPI scores at 52-week. Based on the operational criteria, 60.7% of pure AD patients and 58.8% of MD patients were responders to donepezil. Conclusion：MD patients had similar levels of efficacy with pure AD patients and donepezil was well tolerated in both groups. These results suggest that donepezil is an effective and well-tolerated treatment for MD patients as well as for pure AD patients.

참고문헌 (28)

  1. Lobo A, "Di Carlo A, Breteler MM, et al. Prevalence of dementia and major subtypes in Europe: a collaborative study of population-based cohorts", Neurology, 54(11 Suppl 5), pp.S4~9 (2000)
  2. Frölich L, "Treatment with donepezil in Alzheimer patients with and without cerebrovascular disease", J Neurol, 203, pp.137~139 (2002)
  3. Ott A, "Prevalence of Alzheimer’s disease and vascular dementia: association with education. The Rotterdam Study", BMJ, 310, pp.970~973 (1995)
  4. Wilkinson D, "Donepezil in vascular dementia: a randomized, placebo-controlled study", Neurology, 61, pp.479~486 (2003)
  5. Langa KM, "Mixed dementia: Emerging concepts and therapeutic implications", JAMA, 292, pp.2901~2908 (2004)
  6. Lim A, "Clinico-neuropathological correlation of Alzheimer’s disease in a community-based case series", J Am Geriatr Soc, 47, pp.564~569 (1999)
  7. Snowdon DA, "Brain infarction and the clinical expression of Alzheimer’s disease. The Nun Study", JAMA, 277, pp.813~817 (1997)
  8. McKhann G, "Clinical diagnosis of Alzheimer’s disease", Neurology, 34, pp.939~944 (1984)
  9. Chui HC, "Criteria for the diagnosis of ischemic vascular dementia proposed by the state of California Alzheimer’s Disease Diagnostic and Treatment Centers", Neurology, 42, pp.473~480 (1992)
  10. Zekry D, "Mixed dementia: Epidemiology, diagnosis,and treatment", J Am Geriatr Soc, 50, pp.1431~1438 (2002)
  11. Erkinjuntti T, "Efficacy of galantamine in probable vascular dementia and Alzheimer’s disease combined with cerebrovascular disease: a randomised trial", Lancet, 359, pp.1283~1290 (2002)
  12. Kumar V, "An efficacy and safety analysis of Exelon in Alzheimer’s disease with concurrent vascular risk factors", Eur J Neurol, 7, pp.159~169 (2000)
  13. Blasko I, "Efficacy of donepezil treatment in Alzheimer patients with and without subcortical vascular lesions", Pharmacology, 72, pp.1~5 (2004)
  14. Fazekas F, "MR signal abnormalities at 1.5 T in Alzheimer’s dementia and normal aging", Am J Roentgenol, 149, pp.351~356 (1987)
  15. Kang YW, "A validity study on the Korean Mini-Mental State Examination (K-MMSE) in dementia patients", J Korean Neurol Assoc, 15, pp.300~308 (1997)
  16. Hachinski VC, "Cerebral blood flow in dementia", Arch Neurol, 32, pp.632~637 (1975)
  17. Korean Association for Geriatric Psychiatry, "Korean Assessment Scales for demented patients", pp.72~83 (2003), Hakji-Sa
  18. Rosen WG, "A new rating scale for Alzheimer’s disease", Am J Psychiatry, 141, pp.1356~1364 (1984)
  19. Ku HM, "A study on the reliability and validity of Seoul-Activities of Daily Living (SADL)", J Korean Geriatr Soc, 8, pp.206~214 (2004)
  20. 구형모, "일상활동평가-복합(Seoul-Instrumental Activities of Daily Living ; S-IADL)의 신뢰도 및 타당도 연구", 신경정신의학, 43(2), pp.189~199 (2004), 대한신경정신의학회
  21. Cummings JI, "The neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia", Neurology, 44, pp.2308~2314 (1994)
  22. Choi SH, "Korean version of the neuropsychiatric inventory", J Korean Med Sci, 15, pp.609~615 (2000)
  23. Winblad B, "Pharmacotherapy of Alzheimer’s disease: is there a need to redefine treatment success?", Int J Geriatr Psychiatry, 16, pp.653~666 (2001)
  24. Schindler RJ, "Dementia with cerebrovascular disease: the benefits of early treatment", Eur J Neurol, 12(Suppl 3), pp.17~21 (2005)
  25. Black S, "Efficacy and tolerability of donepezil in vascular dementia:positive results of a 24-week, multicenter, international, randomized,placebo-controlled clinical trial", Stroke, 34, pp.2323~2332 (2003)
  26. Mohs RC, "A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients", Neurology, 57, pp.481~488 (2001)
  27. Gauthier S, "Efficacy of donepezil on behavioral symptoms in patients with moderate-to-severe Alzheimer’s disease", Int Psychogeriatr, 14, pp.389~404 (2002)
  28. Herrmann N, "Galantamine treatment of problematic behavior in Alzheimer’s disease", Am J Geriatr Psychiatry, 13, pp.527~534 (2005)

관련 논문AI추천

알츠하이머병 치매 환자에서 도네페질(Donepezil)에 대한 최초 투약군과 전환군 간의 임상적 효용 비교 평가： 12개월 추적관찰 연구강효신, 김도관, 김혜란, 문유진, 안인숙, 윤지혜, 이영민, 정재원, 황태영대한노인정신의학회 · 노인정신의학2010 · 제14권 제2호갈란타민(Galantamine) 투여 후 순수 알츠하이머병 치매와 혼합성 치매 환자의 주의력, 일상생활능력 및 신경정신행동 증상에 대한 효과 평가강효신, 김도관, 김혜란, 문유진, 안인숙, 윤지혜, 이영민, 황태영대한노인정신의학회 · 노인정신의학2012 · 제16권 제1호알츠하이머 치매 환자에서 치료 전 중증도에 따른 약물의 장기 치료 효과권인선, 김정란, 박유리, 서희원대한생물치료정신의학회 · 생물치료정신의학2021 · 제27권 제1호Efficacy of Galantamine on Cognition in Mild-to-Moderate Alzheimer’s Dementia after Failure to Respond to Donepezil황태영, Doh Kwan Kim, Inn Sook Ahn, Seonwoo Kim대한신경정신의학회 · PSYCHIATRY INVESTIGATION2016 · 제13권 제3호일회 Donepezil 투약이 알쯔하이머병 환자에 미치는 영향 및 반응군 예측 인자로서의 가능성곽용태, 노용우, 양영순대한생물정신의학회 · 생물정신의학2011 · 제18권 제1호알쯔하이머병과 소혈관성 치매에서 Donepezil 복용 후 K-MMSE의 변화와 의미 있는 K-MMSE 변화를 보이는 알쯔하이머병 환자의 특징김준, 곽용태, 이유상, 한일우대한생물정신의학회 · 생물정신의학2005 · 제12권 제2호

이 간행물의 다른 논문 (8건)

노인학대박인수, 김신겸pp. 3-8치매 환자에서의 부적절한 성행동이동현, 김경미pp. 9-14노인과 운전장성만pp. 15-19주요우울증에서 아드레날린 알파 2 수용체 유전자 다형성과 Mirtazapine 치료반응의 연관성에 대한 연관연구김수연, 최홍, 임신원, 김진우, 명우재, 송지혜, 정재원, 이유진, 김도관pp. 20-26치매 선별용 간이정신상태검사(Mini-Mental State Examination for Dementia Screening；MMSE-DS)와 단축형 MMSE-DS(SMMSE-DS)의 한국 노인 정상규준 연구김태희, 김기웅, 추일한, 윤종철, 유승호, 주진형, 박준혁, 김정란, 김문두, 문석우, 이석범, 도연자, 이동우, 한지원pp. 27-37
원문 보기